No Data
No Data
Aquestive Therapeutics Initiated at Outperform by Raymond James
Aquestive Therapeutics Initiated at Outperform by Raymond James
Express News | Raymond James Initiates Coverage On Aquestive Therapeutics With Outperform Rating, Announces Price Target of $7
Aquestive Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 70.32% Raymond James → $7 Initiates Coverage On → Outperform 03/18/2024 118.98% HC Wainwright &
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
Dow Surges 350 Points; Fed Holds Rates Steady
U.S. stocks traded higher toward the end of trading, after the Federal Reserve left rates unchanged. The Dow traded up 0.91% to 39,467.76 while the NASDAQ rose 1.08% to 16,341.42. The S&P 500 also ros
Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher
U.S. stocks traded mostly flat midway through trading, ahead of interest-rate decision from the Federal Reserve. The Dow traded up 0.03% to 39,123.89 while the NASDAQ fell 0.01% to 16,165.15. The S&P
No Data
JESSE JAMES8832OP : oh wow this company's pipeline includs suboxone!! that alone is enough ti carrt the company! imo